Vincrstine
Brand names,
Vincrstine
Analogs
Vincrstine
Brand Names Mixture
Vincrstine
Chemical_Formula
C46H56N4O10
Vincrstine
RX_link
http://www.rxlist.com/cgi/generic3/vincristine.htm
Vincrstine
fda sheet
Vincrstine
msds (material safety sheet)
Vincrstine
Synthesis Reference
No information avaliable
Vincrstine
Molecular Weight
824.958 g/mol
Vincrstine
Melting Point
220 oC
Vincrstine
H2O Solubility
No information avaliable
Vincrstine
State
Solid
Vincrstine
LogP
4.918
Vincrstine
Dosage Forms
Liquid; Solution
Vincrstine
Indication
For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis
Vincrstine
Pharmacology
Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Vincrstine
Absorption
No information avaliable
Vincrstine
side effects and Toxicity
IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg
Vincrstine
Patient Information
PATIENT INFORMATION
Follow the links
http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm
http://www.drugs.com/cons/Vincristine.html
Vincrstine
Organisms Affected
Humans and other mammals